icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays
additive/synergistic effects in in vitro combination studies

 
 
  Reported by Jules Levin AASLD 2016 Nov 11-15 Boston, MA

HCV1

HCV2

HCV3

HCV4

HCV5

HCV6

HCV7